XNAS · Healthcare · Biotechnology
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | Q1 2026 | -0.40 | -0.52 | -30.00% | $0 | ❌ Miss | +0.00% | -0.15% | — |
| 2026-03-31 | Q4 2025 | -0.46 | -0.48 | -4.35% | $0 | ❌ Miss | -0.30% | -0.43% | -0.76% |
| 2025-11-05 |
| Q3 2025 |
| -0.39 |
| -0.41 |
| -5.13% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -0.35 | -0.38 | -8.57% | $0 | ❌ Miss | -1.99% | +1.34% | +32.50% |
| 2025-03-24 | Q4 2024 | -0.35 | -0.58 | -65.71% | $0 | ❌ Miss | -4.93% | -13.53% | -21.65% |
| 2024-08-13 | Q2 2024 | -0.39 | -0.40 | -2.56% | $0 | ❌ Miss | +14.44% | +9.17% | +37.15% |
| 2024-05-13 | Q1 2024 | -0.43 | -0.38 | +11.63% | $0 | ✅ Beat | +2.38% | -1.25% | +9.85% |
| 2024-03-28 | Q4 2023 | -0.48 | -0.38 | +20.83% | $6.9M | ✅ Beat | — | — | — |
Showing last 8 quarters.